BTK and B-cell chronic lymphocytic leukemia: Ibrutinib, at drug concentrations that could block BTK and BCR signaling [27, 28], could not inhibit the capacity of Wnt5a to induce cortactin phosphorylation (Y421) or enhance CLL-cell motility.